Efficacy and Safety of Asciminib, a Specific Allosteric BCR-ABL1 Inhibitor Targeting the Myristoyl-Binding Site, in Patients with Chronic Myeloid Leukemia (CML) Carrying the T315I Mutation
Year: 2019
Type: article
Authors: Michael W. Deininger, Delphine Réa, Fabian Lang, Dong-Wook Kim, Jorge E. Cortes, Timothy P. Hughes, Hironobu Minami, Massimo Breccia, Daniel J. DeAngelo, Andreas Hochhaus, Moshe Talpaz, Yeow Tee Goh, Philipp D. Le Coutre, Gabriel Etienne, Manu Sondhi, Kaushal Mishra, Paola Aimone, Michael J. Mauro
Institutions: Huntsman Cancer Institute, Hôpital Saint-Louis, Goethe University Frankfurt, The Catholic University of Korea Seoul St. Mary's Hospital, Catholic University of Korea, The University of Texas MD Anderson Cancer Center, South Australian Health and Medical Research Institute, The University of Adelaide, Kobe University Hospital, Sapienza University of Rome, Dana-Farber Cancer Institute, Jena University Hospital, University of Michigan, Singapore General Hospital, Charité - Universitätsmedizin Berlin, Institut Bergonié, Novartis (Switzerland), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2970404420